Gyre Therapeutics, Inc. operates as a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 593 full-time employees. The company went IPO on 2006-04-12. The firm is engaged in the research, development, manufacturing, and commercialization of drugs for organ fibrosis. The company is primarily focused on the development and commercialization of F351 (Hydronidone) for the treatment of Nonalcoholic Steatohepatitis Treatment (NASH)-associated fibrosis. The firm is also advancing a diverse pipeline in the China through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. The firm operates through two segments: Gyre Pharmaceuticals, and Gyre after the Contributions. The Gyre Pharmaceuticals has one major commercial drug product, ETUARY, and several product candidates in pre-clinical and clinical development. Gyre is a biopharmaceutical company focused on the development and commercialization of F351 for the treatment of non-alcoholic steatohepatitis-associated liver fibrosis in the United States.

GYRE Profile, Market Tickers and Other

GYRE profile